Literature DB >> 15566354

Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies.

Anthony J Bench1, Juan Li, Brian J P Huntly, Eric Delabesse, Nasios Fourouclas, Adrienne R Hunt, Panos Deloukas, Anthony R Green.   

Abstract

Chromosome 20q deletion is a recurrent chromosomal abnormality associated with myeloid malignancies. L3MBTL represents a strong candidate tumour suppressor gene since it lies within the common deleted region, is a member of the Polycomb-like family, encodes the human homologue of a Drosophila tumour suppressor and is expressed within haematopoietic progenitor cells. We describe the structure of L3MBTL, identify two putative promoters each associated with two CpG islands and characterize a complex pattern of alternative splicing events. Mutation analysis of the gene in patients with and without a 20q deletion identified several polymorphisms but no acquired mutations. The two CpG islands spanning promoter 2 undergo monoallelic methylation in normal haematopoietic cells consistent with imprinting of L3MBTL. Samples from patients with a 20q deletion retained either the methylated or unmethylated allele but retention of the methylated allele did not correlate with reduction in L3MBTL mRNA levels. The absence of a correlation between L3MBTL methylation and transcription could be shown to reflect loss of imprinting in one patient. In addition, our results demonstrate that inactivation of L3MBTL is not a common occurrence in patients with a 20q deletion or in cytogenetically normal patients with polycythaemia vera.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15566354     DOI: 10.1111/j.1365-2141.2004.05278.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors:  S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal:  Ir J Med Sci       Date:  2007-04-18       Impact factor: 1.568

2.  Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21.

Authors:  Qian An; Sarah L Wright; Anthony V Moorman; Helen Parker; Mike Griffiths; Fiona M Ross; Teresa Davies; Christine J Harrison; Jon C Strefford
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 3.  Chromatin regulation: how complex does it get?

Authors:  Karin Meier; Alexander Brehm
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

4.  Clinical Correlates of Autosomal Chromosomal Abnormalities in an Electronic Medical Record-Linked Genome-Wide Association Study: A Case Series.

Authors:  Hayan Jouni; Khader Shameer; Yan W Asmann; Ribhi Hazin; Mariza de Andrade; Iftikhar J Kullo
Journal:  J Investig Med       Date:  2013-10       Impact factor: 2.895

5.  Mosaic chromosome 20q deletions are more frequent in the aging population.

Authors:  Mitchell J Machiela; Weiyin Zhou; Neil Caporaso; Michael Dean; Susan M Gapstur; Lynn Goldin; Nathaniel Rothman; Victoria L Stevens; Meredith Yeager; Stephen J Chanock
Journal:  Blood Adv       Date:  2017-02-13

6.  Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera.

Authors:  Fabiana Perna; Nadia Gurvich; Ruben Hoya-Arias; Omar Abdel-Wahab; Ross L Levine; Takashi Asai; Francesca Voza; Silvia Menendez; Lan Wang; Fan Liu; Xinyang Zhao; Stephen D Nimer
Journal:  Blood       Date:  2010-06-28       Impact factor: 22.113

Review 7.  Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.

Authors:  L Benetatos; G Vartholomatos
Journal:  Leukemia       Date:  2015-02-23       Impact factor: 11.528

8.  Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

Authors:  Athar Aziz; E Joanna Baxter; Carol Edwards; Clara Yujing Cheong; Mitsuteru Ito; Anthony Bench; Rebecca Kelley; Yvonne Silber; Philip A Beer; Keefe Chng; Marilyn B Renfree; Kirsten McEwen; Dionne Gray; Jyoti Nangalia; Ghulam J Mufti; Eva Hellstrom-Lindberg; Jean-Jacques Kiladjian; Mary Frances McMullin; Peter J Campbell; Anne C Ferguson-Smith; Anthony R Green
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

9.  Loss, mutation and deregulation of L3MBTL4 in breast cancers.

Authors:  Lynda Addou-Klouche; José Adélaïde; Pascal Finetti; Nathalie Cervera; Anthony Ferrari; Ismahane Bekhouche; Fabrice Sircoulomb; Christos Sotiriou; Patrice Viens; Soraya Moulessehoul; François Bertucci; Daniel Birnbaum; Max Chaffanet
Journal:  Mol Cancer       Date:  2010-08-10       Impact factor: 27.401

Review 10.  MBT domain proteins in development and disease.

Authors:  Roberto Bonasio; Emilio Lecona; Danny Reinberg
Journal:  Semin Cell Dev Biol       Date:  2009-09-22       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.